Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug pricing

MS drug approved by NICE after NHS renegotiates price

A new drug to treat some adults with multiple sclerosis (MS) is now being recommended for use by the National Institute for Health and Care Excellence (NICE) after the NHS renegotiated a lower price with the manufacturer Roche.

On 9 May 2019, NICE declared that it was reversing its previous draft guidance decision not to recommend ocrelizumab (marketed as Ocrevus) for treating primary progressive MS (PPMS) in adults.

Meindert Boysen, director of NICE’s centre for health technology evaluation, said: “Our earlier draft guidance acknowledged that ocrelizumab represents an important development in the treatment of a condition for which there is a large unmet need. Unfortunately we couldn’t recommend it at the price offered at that time because it did not represent a cost-effective use of limited NHS resources.

“We are … pleased that NHS England and the company have been able to reach an agreement that will see this important new treatment made available to thousands of people with this form of MS.”

Simon Stevens, chief executive of NHS England, described the deal struck with Roche as “innovative”, attributing its success to a flexible and thorough negotiation process.

Around 14% of the 90,000 people in England with MS have the PPMS form.

Roche estimates that around 2,700 people could now be eligible for ocrelizumab, which is administered as an infusion every six months. The average full price cost per patient per year is £19,160.

Details of the price deal have been kept confidential.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206521

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Prescribing Medicines for Children

    Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

    £60.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.